Tag: Prescription Drugs

Sustained reduction seen in body weight versus placebo for adults aged 18 to 75 with overweight or obesity, without diabetes

Defect-free quadruple medication therapy significantly improved at discharge, 30 days in patients with heart failure with reduced ejection fraction

0.5 percent with obesity were prescribed an obesity medication in 2023; 83 percent of prescriptions received by teens with severe obesity

Greater reduction in urinary albumin-to-creatinine ratio seen for combination versus either agent alone

Dapagliflozin results in more patients with improved or resolved MASH without worsening of fibrosis, improved fibrosis without worsening of MASH

Risk for major adverse cardiac and cerebrovascular events lower compared with aspirin monotherapy for patients who undergo PCI and discontinue DAPT

Better event-free survival outcomes seen for durvalumab plus FLOT versus FLOT alone in phase 3 randomized trial

PrEP dispensing and initiation have increased but PrEP persistence has decreased

Findings seen in women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer

Best corrected visual acuity improved 9.8 letters with lamivudine after four weeks, decreased 1.8 letters with placebo